Form 4: C4 Therapeutics Director Donna Grogan Acquires Shares in Lieu of Cash Compensation

Director Donna Grogan acquired 3,757 shares of C4 Therapeutics common stock in lieu of cash compensation, while disposing of 32,699 shares.

Summary

• On January 2, 2025, Donna Grogan, a director of C4 Therapeutics, acquired 3,757 shares of common stock.
• The acquisition was made in accordance with the Issuer's Non-Employee Director Compensation Policy, where Ms. Grogan elected to receive shares in lieu of cash compensation.
• The price of the stock was $3.66 per share, based on the closing market price on January 2, 2025.
• Following the transaction, Ms. Grogan directly owns 32,699 shares of C4 Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a director receiving shares in lieu of cash compensation. While it could be seen as a positive sign of confidence, it's not a major event.

Positives

• A director's decision to take shares in lieu of cash compensation could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry. Directors often receive stock options or shares as part of their compensation packages.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it involves a relatively small number of shares.

Key Dates